Omeros vs Pharming Group NV: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Omeros Corporation (OMER)

Q3 20268 Jul – 28 Jul 2026

▼2▲1

Omeros Hit by EU Setback and Lawsuits, Then Rival's Trial Failure Lifts Shares

EU rejection triggers securities investigations Multiple law firms are investigating Omeros for possible securities fraud after European regulators rejected its drug narsoplimab for a rare blood disorder. This legal cloud could lead to costly class actions and keeps pressure on the stock, as investors worry about management's disclosures.
This is a new negative development that directly weighs on OMER's price and investor confidence.
Analyst cuts price target on EU rejection H.C. Wainwright lowered its price target for Omeros from $40 to $33, removing the European market opportunity for narsoplimab and factoring in higher research spending. The analyst still rates the stock a Buy, but the cut reflects a smaller potential payoff.
This shows a concrete reassessment of OMER's value following the EU setback, which can influence investor expectations.
Rival's trial failure boosts Omeros' competitive position AstraZeneca's competing drug Ultomiris failed a late-stage trial in the same rare blood disorder that Omeros' Yartemlea treats. This removes a major competitive threat, making it easier for Omeros to grow Yartemlea sales in the U.S., and the stock jumped on the news.
This is a new positive catalyst that directly improves OMER's commercial outlook and drove a sharp share price increase.

July 20268 Jul – 28 Jul 2026

▼2▲1

Omeros Hit by EU Setback and Lawsuits, Then Rival's Trial Failure Lifts Shares

EU rejection triggers securities investigations Multiple law firms are investigating Omeros for possible securities fraud after European regulators rejected its drug narsoplimab for a rare blood disorder. This legal cloud could lead to costly class actions and keeps pressure on the stock, as investors worry about management's disclosures.
This is a new negative development that directly weighs on OMER's price and investor confidence.
Analyst cuts price target on EU rejection H.C. Wainwright lowered its price target for Omeros from $40 to $33, removing the European market opportunity for narsoplimab and factoring in higher research spending. The analyst still rates the stock a Buy, but the cut reflects a smaller potential payoff.
This shows a concrete reassessment of OMER's value following the EU setback, which can influence investor expectations.
Rival's trial failure boosts Omeros' competitive position AstraZeneca's competing drug Ultomiris failed a late-stage trial in the same rare blood disorder that Omeros' Yartemlea treats. This removes a major competitive threat, making it easier for Omeros to grow Yartemlea sales in the U.S., and the stock jumped on the news.
This is a new positive catalyst that directly improves OMER's commercial outlook and drove a sharp share price increase.

Latest8 Jul – 28 Jul 2026

▼2▲1

Omeros Hit by EU Setback and Lawsuits, Then Rival's Trial Failure Lifts Shares

EU rejection triggers securities investigations Multiple law firms are investigating Omeros for possible securities fraud after European regulators rejected its drug narsoplimab for a rare blood disorder. This legal cloud could lead to costly class actions and keeps pressure on the stock, as investors worry about management's disclosures.
This is a new negative development that directly weighs on OMER's price and investor confidence.
Analyst cuts price target on EU rejection H.C. Wainwright lowered its price target for Omeros from $40 to $33, removing the European market opportunity for narsoplimab and factoring in higher research spending. The analyst still rates the stock a Buy, but the cut reflects a smaller potential payoff.
This shows a concrete reassessment of OMER's value following the EU setback, which can influence investor expectations.
Rival's trial failure boosts Omeros' competitive position AstraZeneca's competing drug Ultomiris failed a late-stage trial in the same rare blood disorder that Omeros' Yartemlea treats. This removes a major competitive threat, making it easier for Omeros to grow Yartemlea sales in the U.S., and the stock jumped on the news.
This is a new positive catalyst that directly improves OMER's commercial outlook and drove a sharp share price increase.

Pharming Group NV (PHARM.AS)

Q3 202630 Jul – 29 Sep 2026

▼3▲1

Pharming hit by guidance cut and CEO exit, offset by Joenja label wins

Q2 miss and $30M guidance cut Pharming's Q2 revenue of $90.2M missed estimates and full-year guidance was cut by $30M, mainly because legacy RUCONEST sales fell 10% on lower volume. Shares dropped 15% as investors re-priced slower growth. This is the core reason the stock is weaker.
The guidance cut is the single biggest negative force behind the stock's move this period.
Securities investigation adds legal overhang Law firm Levi & Korsinsky is investigating whether Pharming failed to warn investors about RUCONEST competition and demand pressure before the Q2 miss. Such probes can lead to lawsuits, cost money and keep a cloud over the shares, weighing on sentiment.
It is a new negative overhang that can affect the stock beyond the one-day drop.
Joenja expands in Japan and to young US children Joenja launched in Japan and won FDA approval for children aged 4-11 in the US, widening the patient pool for Pharming's growth drug. More eligible patients should lift future Joenja sales, the main offset to RUCONEST's decline.
These approvals are the main positive counterweight to the weak RUCONEST story.
CEO exits abruptly, interim co-CEOs take over CEO Fabrice Chouraqui stepped down immediately after the board and he disagreed on strategy, with two executives named interim co-CEOs. Leadership churn creates uncertainty about execution just as the company needs to steady RUCONEST and grow Joenja, pressuring the shares.
An abrupt CEO departure is a fresh governance risk that can hold the stock back.

August 202630 Jul – 29 Sep 2026

▼3▲1

Pharming hit by guidance cut and CEO exit, offset by Joenja label wins

Q2 miss and $30M guidance cut Pharming's Q2 revenue of $90.2M missed estimates and full-year guidance was cut by $30M, mainly because legacy RUCONEST sales fell 10% on lower volume. Shares dropped 15% as investors re-priced slower growth. This is the core reason the stock is weaker.
The guidance cut is the single biggest negative force behind the stock's move this period.
Securities investigation adds legal overhang Law firm Levi & Korsinsky is investigating whether Pharming failed to warn investors about RUCONEST competition and demand pressure before the Q2 miss. Such probes can lead to lawsuits, cost money and keep a cloud over the shares, weighing on sentiment.
It is a new negative overhang that can affect the stock beyond the one-day drop.
Joenja expands in Japan and to young US children Joenja launched in Japan and won FDA approval for children aged 4-11 in the US, widening the patient pool for Pharming's growth drug. More eligible patients should lift future Joenja sales, the main offset to RUCONEST's decline.
These approvals are the main positive counterweight to the weak RUCONEST story.
CEO exits abruptly, interim co-CEOs take over CEO Fabrice Chouraqui stepped down immediately after the board and he disagreed on strategy, with two executives named interim co-CEOs. Leadership churn creates uncertainty about execution just as the company needs to steady RUCONEST and grow Joenja, pressuring the shares.
An abrupt CEO departure is a fresh governance risk that can hold the stock back.

Latest30 Jul – 29 Sep 2026

▼3▲1

Pharming hit by guidance cut and CEO exit, offset by Joenja label wins

Q2 miss and $30M guidance cut Pharming's Q2 revenue of $90.2M missed estimates and full-year guidance was cut by $30M, mainly because legacy RUCONEST sales fell 10% on lower volume. Shares dropped 15% as investors re-priced slower growth. This is the core reason the stock is weaker.
The guidance cut is the single biggest negative force behind the stock's move this period.
Securities investigation adds legal overhang Law firm Levi & Korsinsky is investigating whether Pharming failed to warn investors about RUCONEST competition and demand pressure before the Q2 miss. Such probes can lead to lawsuits, cost money and keep a cloud over the shares, weighing on sentiment.
It is a new negative overhang that can affect the stock beyond the one-day drop.
Joenja expands in Japan and to young US children Joenja launched in Japan and won FDA approval for children aged 4-11 in the US, widening the patient pool for Pharming's growth drug. More eligible patients should lift future Joenja sales, the main offset to RUCONEST's decline.
These approvals are the main positive counterweight to the weak RUCONEST story.
CEO exits abruptly, interim co-CEOs take over CEO Fabrice Chouraqui stepped down immediately after the board and he disagreed on strategy, with two executives named interim co-CEOs. Leadership churn creates uncertainty about execution just as the company needs to steady RUCONEST and grow Joenja, pressuring the shares.
An abrupt CEO departure is a fresh governance risk that can hold the stock back.